Vancouver, British Columbia--(Newsfile Corp. - February 26, 2025) - Moss Genomics Inc. (CSE: MOSS) (FSE: F73) ("Moss" or the "Company") is pleased to announce the appointment of Joseph De Pinto to its Board of Directors and Michal "Mickey" Goldstein as its new fractional Chief Financial Officer (CFO).
Having served as a co-founder in several blockchain-based companies as well as Barpay, which pioneered digital payments at over 15,000 bars and restaurants over the past decade, Mr. De Pinto brings significant expertise in blockchain technology and data security. His experience will be a key asset as the Company continues to integrate advanced blockchain solutions into its genomics platform.
Engaging Crowe MacKay LLP to facilitate the transition of CFO, Moss Genomics is confident that Ms. Goldstein's extensive financial expertise and leadership experience will be instrumental in supporting the Company's continued expansion and operational efficiency.
The Company would like to thank former Director Martin Bajic and former CFO Hani Zabaneh for their contributions and wishes them well in their future endeavors.
The Company remains focused on advancing its genomics platform with blockchain-driven security and privacy while strategically expanding its Ethereum treasury.
About Moss Genomics Inc.
Moss Genomics is a biotechnology company focused on genomics and microbiome research to develop advanced genetic insights and solutions. The company leverages blockchain technology to enhance security and user control over genomic information. Along with its genomics-focused products, Moss Genomics deploys an Ethereum accumulation strategy as part of its treasury management, currently holding 160 ETH on its balance sheet.
For further information concerning Moss and its business, please view the Company's website at https://mossgenomics.com/ and its SEDAR+ profile at www.sedarplus.ca or contact us at:
CONTACT INFORMATION
Moss Genomics Inc.
Jack Liu, Chief Executive Officer and Director
Email: invest@mossgenomics.com
Telephone: 604-710-0124
The CSE has neither approved nor disapproved the contents of this news release. Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Information
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. Forward-Looking statements relate to future events or future performance and reflect the expectations or beliefs of management of the Company regarding future events. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or "occur". This information and these statements, referred to herein as "forward-looking statements", are not historical facts, are made as of the date of this news release and include without limitation, statements regarding discussions of future plans, estimates and forecasts and statements as to management's expectations and intentions with respect to, among other things: the Company's intention to leverage the blockchain to advance its genomics business; the Company's belief that blockchain technology will enhance data security, privacy, and user control over genomic information; the Company's belief that Ethereum will represent a viable alternative to traditional fiat currencies as part of the Company's treasury management system; and the Company's belief with respect to engagement of its new CFO being instrumental in supporting the Company's continued expansion and operational efficiency.
These forward-looking statements involve numerous risks and uncertainties and actual results might differ materially from results suggested in any forward-looking statements. These risks and uncertainties include, among other things: the risk that the Company will be unable to utilize the blockchain in an effective manner for the advancement of its genomics business; the risk that the blockchain technology will not notably enhance data security, privacy or user control over genetic information; the risk that Ethereum will not represent a viable alternative to traditional fiat currencies for use in a treasury management system; and the risk that its agreement with Crowe MacKay LLP and engagement of its new CFO will not proceed as anticipated.
In making the forward-looking statements in this news release, the Company has applied several material assumptions, including without limitation, that: blockchain technologies can be effectively implemented into the Company's genomics business model and can be implemented in a cost-effective and timely manner; the privacy and security offered by decentralized blockchain technology will be superior to the privacy and security over user data which may be available through other means; that the Company's use of blockchain as part of its business model will improve access to genetic insights; that the use of Ethereum in the Company's treasury management system will reflect a viable alternative to traditional fiat currencies, including the risk that commercial partners of the Company are or become unwilling to accept Ethereum as consideration for products and services; and that its agreement with Crowe MacKay LLP and engagement of its new CFO will proceed as anticipated.
Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/242433
SOURCE: Moss Genomics Inc.
